Sunshine Biopharma Inc., of Montreal, signed an agreement with the Jewish General Hospital to advance lead compound Adva-27a through preclinical development and Phase I trials. Adva-27a is a small-molecule Topoisomerase II inhibitor. Sunshine also has a similar agreement with the Research Foundation of the State University of New York, acting on behalf of Binghamton University, of Binghamton, N.Y.